Patrick Neven
Impact in
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- Cancer Risks and Factors
- Cancer survivorship and care
Papers in
- Cancer Research 169
- Breast Cancer Treatment Studies 153
- Oncology 121
- Cancer Risks and Factors 30
- Co-authors
- Ignace B. Vergote (119 shared papers)Frédéric Amant (90 shared papers)Philippe Moerman (28 shared papers)Erik Van Limbergen (29 shared papers)Dirk Timmerman (25 shared papers)Hans P. M. W. Wildiers (123 shared papers)Robert Paridaens (68 shared papers)Ann Smeets (82 shared papers)
- Journals
- Annals of Oncology (56 papers)Breast Cancer Research and Treatment (49 papers)Journal of Clinical Oncology (31 papers)European Journal of Cancer (27 papers)International Journal of Gynecological Cancer (25 papers)
- Partner nations
- BelgiumUnited StatesGermany
In The Last Decade
Patrick Neven
507 papers receiving 29.2k citations
Patrick Neven's Hit Papers
Peers
Comparison fields: 5 of 156
- Cancer Research 7.2k
- Oncology 6k
- Pulmonary and Respiratory Medicine 6.7k
- Obstetrics and Gynecology 1.9k
- Genetics 5.3k
Countries citing papers authored by Patrick Neven
This map shows the geographic impact of Patrick Neven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Neven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Neven more than expected).
Fields of papers citing papers by Patrick Neven
This network shows the impact of papers produced by Patrick Neven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Neven. The network helps show where Patrick Neven may publish in the future.
Co-authors
The 25 scholars most cited alongside Patrick Neven, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 534 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy Hit paper breakdown → | 2017 | 1340 |
| 2 | Endometrial cancer Hit paper breakdown → | 2005 | 1260 |
| 3 | Association analysis identifies 65 new breast cancer risk loci Hit paper breakdown → | 2017 | 1040 |
| 4 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 Hit paper breakdown → | 2018 | 872 |
| 5 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes Hit paper breakdown → | 2018 | 775 |
| 6 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 Hit paper breakdown → | 2019 | 767 |
| 7 | Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) Hit paper breakdown → | 2020 | 728 |
| 8 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer Hit paper breakdown → | 2019 | 615 |
| 9 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer Hit paper breakdown → | 2021 | 592 |
| 10 | Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies Hit paper breakdown → | 2010 | 575 |
| 11 | Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial Hit paper breakdown → | 2022 | 527 |
| 12 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer Hit paper breakdown → | 2015 | 489 |
| 13 | Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 Hit paper breakdown → | 2014 | 478 |
| 14 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche Hit paper breakdown → | 2014 | 467 |
| 15 | Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 404 |
| 16 | 2007 | 384 | |
| 17 | 2013 | 349 | |
| 18 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 19 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair Hit paper breakdown → | 2015 | 324 |
| 20 | Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses Hit paper breakdown → | 2020 | 321 |
About Patrick Neven
Patrick Neven is a scholar working on Cancer Research, Oncology, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Genetics, having authored 534 papers that have together received 30.1k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (153 papers), Advanced Breast Cancer Therapies (100 papers), Endometrial and Cervical Cancer Treatments (49 papers), Estrogen and related hormone effects (47 papers), Cancer Risks and Factors (30 papers), BRCA gene mutations in cancer (26 papers), Menopause: Health Impacts and Treatments (25 papers) and Genetic Associations and Epidemiology (24 papers). The work is most often cited by research in Cancer Research (7.2k citations), Oncology (6k citations), Pulmonary and Respiratory Medicine (6.7k citations), Obstetrics and Gynecology (1.9k citations) and Genetics (5.3k citations). Patrick Neven has collaborated with scholars based in Belgium, United States and Germany. Frequent co-authors include Ignace B. Vergote, Frédéric Amant, Philippe Moerman, Erik Van Limbergen, Dirk Timmerman, Hans P. M. W. Wildiers, Robert Paridaens, Ann Smeets, Marie-Rose Christiaens and Karin Leunen. Their work appears in journals such as Annals of Oncology, Breast Cancer Research and Treatment, Journal of Clinical Oncology, European Journal of Cancer and International Journal of Gynecological Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.